<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844373</url>
  </required_header>
  <id_info>
    <org_study_id>AY:APL:OPD</org_study_id>
    <nct_id>NCT03844373</nct_id>
  </id_info>
  <brief_title>Tolerance and Acceptability Evaluation of STOCKHOLM</brief_title>
  <official_title>Tolerance and Acceptability Evaluation of STOCKHOLM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aymes International Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aymes International Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tolerance and Acceptability of new oral nutritional supplement - STOCKHOLM.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate tolerance and acceptability of 'STOCKHOLM' in patients requiring supplementary
      oral nutritional support compared with currently available alternatives.

      To obtain data to support an ACBS submissions for 'STOCKHOLM' (to allow for prescription in
      the community at NHS expense).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GI Tolerance</measure>
    <time_frame>9 Days</time_frame>
    <description>To assess gastro-intestinal tolerance of 'STOCKHOLM' in patients in the community requiring oral nutritional supplementation. Monitoring includes recording the number and consistency of bowel movements as assessed on the Bristol stool form scale, any episodes of nausea, vomiting, abdominal pain, bloating or diarrhoea.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acceptability and Palatability of Consuming the Nutritional Supplement: Questionnaire</measure>
    <time_frame>9 days</time_frame>
    <description>To assess the acceptability of 'STOCKHOLM' in patients in the community requiring oral nutritional supplementation. At the end of the intervention period an acceptability and preference questionnaire will be completed by the patient in order to seek their opinion on the taste, smell, texture and overall liking of the new supplement drink.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance with Prescription of STOCKHOLM</measure>
    <time_frame>9 days</time_frame>
    <description>Recording of amount of STOCKHOLM consumed by subjects compared to amount prescribed. Good compliance = &gt;80% of prescribed being consumed. Same data collected for baseline product and compared with that of STOCKHOLM.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Malnutrition</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients established on an oral nutritional supplement, being prescribed oral nutritional supplement (ONS) providing at least 300 kcal/day will be changed onto an equivalent prescription of STOCKHOLM for a period of 9 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>STOCKHOLM</intervention_name>
    <description>STOCKHOLM is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision.</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are able to communicate their views regarding acceptability.

          -  Patients established on an oral nutritional supplement, being prescribed ONS providing
             approximately 300 kcal/day

          -  Patients expected to require oral nutritional supplementation for at least 2 further
             weeks.

          -  Informed consent obtained.

        Exclusion Criteria:

          -  Participation in any other studies involving investigational or marketed products
             concomitantly or within two weeks prior to entry into the study

          -  Patients requiring a milk free diet

          -  Patients with medical or dietary contraindication to any feed ingredients (see
             appendix 2 of protocol for full list)

          -  Patients with significant renal or hepatic impairment

          -  Patients with dysphagia requiring stage 1,2 or 3 thickened fluids

          -  Patients with uncontrolled inflammatory bowel disease or previous bowel resection with
             ongoing gastrointestinal symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gemma Fry</name>
      <address>
        <city>Haywards Heath</city>
        <zip>RH16 9PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gemma Fry</last_name>
      <phone>7384463214</phone>
      <email>gfry@aymes.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 6, 2019</study_first_submitted>
  <study_first_submitted_qc>February 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

